SOOKMYUNG WOMEN'S UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION;숙명여자대학교산학협력단;SOOKMYUNG WOMEN&primeS UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
发明人:
YOON, SUK JOON,윤석준,NINGNING HE,허닝닝,KIM, NA YOUNG,김나영,CHO, YONG YEON,조용연,YOON, SUK JOONKR,NINGNING HECN,KIM, NA YOUNGKR,CHO, YONG YEONKR
申请号：
KR1020150038485
公开号：
KR1020150110385A
申请日:
2015.03.19
申请国别(地区):
KR
年份:
2015
代理人:
摘要：
The present invention relates to a pharmaceutical composition for treating STK11-mutation cancer, containing, as an active ingredient, a material inhibiting a sodium-potassium transport function of Na+-K+ ATPase (ATP1A1)； an anticancer drug containing the composition as an active ingredient； and a method for screening STK11-mutation cancer therapeutic agent. It was first established that, of cancer cells in which various gene mutations are confirmed, an STK11-mutation cancer cell line, which is confirmed at high frequency, was treated with cardiac glycosides as a material inhibiting a sodium-potassium transport function of Na+-K+ ATPase (ATP1A1), to significantly inhibit the growth of cancer cells. Therefore, the material inhibiting a sodium-potassium transport function of Na+-K+ ATPase (ATP1A1) can be a target for treating STK11-mutation-derived cancer.본 발명은 Na+-K+ ATPase (ATP1A1)의 나트륨-칼륨 수송 기능을 저해하는 물질을 유효성분으로 포함하는 STK11-돌연변이 암 치료용 약학적 조성물, 상기 조성물을 유효성문으로 포함하는 항암제 및 STK11-돌연변이 암 치료제의 스크리닝 방법 등에 관한 것이다. 암세포에서는 다양한 유전자의 돌연변이가 확인되는데 그 중 높은 빈도로 확인되는 STK11-돌연변이 암 세포주에 Na+-K+ ATPase (ATP1A1)의 나트륨-칼륨 수송 기능을 저해하는 물질인 강심 배당체(Cardiac glycosides)를 처리함으로써 암 세포의 성장이 현저하게 저해됨을 최초로 규명하였다. 따라서 본 발명에 따른 Na+-K+ ATPase (ATP1A1)의 나트륨-칼륨 수송 기능을 저해하는 물질은 STK11-돌연변이 유래 암의 치료 타겟이 될 수 있는 효과가 있다.
